The introduction of pill versions of GLP-1 drugs and their declining costs are poised to disrupt the food and beverage industry significantly. As these medications gain traction among U.S. adults—currently affecting one in eight—the implications for restaurants and packaged food manufacturers are profound. Users report consuming 21% fewer calories, leading to potential losses of $30 billion to $55 billion in annual sales for the sector by 2030, according to JPMorgan.
This shift towards lower-calorie consumption is already impacting dining habits, with many GLP-1 users dining out less frequently and opting for healthier snack options. Notably, about 60% of users are cutting back on restaurant visits, particularly during dinner hours. Companies like PepsiCo and Domino’s are adapting their menus to cater to health-conscious consumers, indicating a trend towards innovation in product offerings.
For market professionals, the key takeaway is that the rise of GLP-1 drugs presents both challenges and opportunities. Brands that pivot to healthier, protein-rich options may not only mitigate risks but also capture a growing segment of health-focused consumers.
Source: cnbc.com